36
Participants
Start Date
April 30, 2019
Primary Completion Date
May 17, 2024
Study Completion Date
May 17, 2024
CG-806
CG-806 will be given orally in ascending doses starting at 150 mg PO BID until the maximum tolerated dose or recommended dose is reached.
Manhattan Hematology Oncology, New York
Memorial Sloan Kettering Cancer Center, New York
The Center for Cancer and Blood Disorders a division of American Oncology Partners of Maryland, PA, Bethesda
University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore
Virginia Oncology Associates, Norfolk
Prisma Health - ITOR, Greenville
Carolina Blood and Cancer Care Associates, Rock Hill
Mayo Clinic Jacksonville, Jacksonville
Orlando Health, Orlando
Fort Wayne Medical Oncology and Hematology, Fort Wayne
University of Michigan, Ann Arbor
Mayo Clinic Rochester, Rochester
SCL Health, St. Vincent Frontier Cancer Center, Billings
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Texas Oncology - Tyler, Tyler
Texas Oncology - Fort Worth Cancer Center, Fort Worth
University of Texas, M.D. Anderson Cancer Center, Houston
University of Texas Health Science Center at San Antonio, Mays Cancer Center, San Antonio
Texas Oncology - Austin-Midtown, Austin
Rocky Mountain Cancer Centers, Aurora
University of California Los Angeles, Los Angeles
Torrance Memorial Physician Network, Redondo Beach
UCSD Moores Cancer Center, San Diego
Sharp Clinical Oncology Research, San Diego
Ridley-Tree Cancer Center, Santa Barbara
Pacific Cancer Care, Monterey
St. Joseph Heritage Heathcare, Santa Rosa
Northwest Cancer Specialists, P.C. - Compass Oncology, Vancouver
UMass Memorial Medical Center, Worcester
Morristown Medical Center, Morristown
Lead Sponsor
Aptose Biosciences Inc.
INDUSTRY